Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…
Revance Therapeutics, Inc. $190 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…